COVID-19 Treatments

COVID-19 Treatments

Rolling Collaborative Reviews (RCR)

Please access the RCR project plan and all separate RCR documents, updated on a monthly or bi-monthly basis, in the following table.

Note: Due to the EUnetHTA Assembly & Forum that is taking place on the 14-15 April 2021, the publication of the April round of RCRs will be shifted to the 20 April.

Project ID Title Version of RCR published Author Start of Procedure  Continuation Publication of Project Plan
RCR01 Convalescent plasma therapy / CPT 10.0 – 18/05/21 HTW August 2020 No, stopped since May 2021 01.07.2020 – RCRs Project Plan
RCR02 Lopinavir + Ritonavir 4.0 – 23/11/20 National Institute of Pharmacy and Nutrition – NIPN August 2020 No, stopped since November 2020  
RCR03 Tocilizumab 10.0 – 18/05/21 National Institute of Pharmacy and Nutrition – NIPN August 2020 No, stopped since May 2021  
RCR04 Camostat 10.0 – 15/07/21 Belgian Health Care Knowledge Centre – KCE August 2020 Yes, monthly  
RCR05 Nafamostat 7.0 – 18/05/21 Belgian Health Care Knowledge Centre – KCE August 2020 Yes, monthly  
RCR06 Solnatide 6.0 – 18/05/21 Austrian Institute for Health Technology Assessment – AIHTA August 2020 No, stopped since May 2021  
RCR07 Anakinra 14.0 – 17/09/21 Austrian Institute for Health Technology Assessment – AIHTA August 2020 Yes, monthly  
RCR08 Dexamethasone 2.0 – 15/09/20 Austrian Institute for Health Technology Assessment – AIHTA August 2020 No, stopped since October 2020  19.11.2020 – PTRCR18 Dexamethasone
RCR09 APN01 7.0 – 15/07/21 Agencia Española De Medicamentos Y Productos Sanitarios – AEMPS, Andalusian HTA Agency,
Ministry of Health – AETSA
August 2020 Yes, bi-monthly  
RCR10 Darunavir 9.0 – 18/05/21 Swiss Network for HTA – SNHTA August 2020 No, stopped since May 2021  
RCR11 Favipiravir 10.0 – 18/05/21 Swiss Network for HTA – SNHTA August 2020 No, stopped since May 2021  
RCR12 Sarilumab 10.0 – 18/05/21 Norwegian Institute of Public Health – NIPH August 2020 No, stopped since May 2021  
RCR13 Interferon and Novaferon 9.0 – 18/05/21 Norwegian Institute of Public Health – NIPH September 2020 No, stopped since May 2021  
RCR14 Gimsilumab 3.0 – 18/05/21 State Medicines Control Agency of Lithuania – SMCA August 2020 No, stopped since May 2021  
RCR15 Canakinumab 5.0 – 18/05/21 State Medicines Control Agency of Lithuania – SMCA August 2020 No, stopped since May 2021  
RCR16 REGN-COV2 (Casirivimab + Imdevimab) 3.0 – 15/02/21 Austrian Institute for Health Technology Assessment – AIHTA December 2020 No, stopped with February 2021 20.05.2021 – PTRCR19 REGN-COV2
RCR17 Bamlanivimab (LY-CoV555) 3.0 – 15/02/21 Austrian Institute for Health Technology Assessment – AIHTA December 2020 No, stopped with February 2021 31.05.2021 – PTRCR20 Bamlanivimab
RCR18 Baricitinib (LY3009104) 10.0 – 17/09/21 Austrian Institute for Health Technology Assessment – AIHTA December 2020 Yes, monthly  
RCR19 Molnupiravir (MK 4482/ EIDD-2801 6.0 – 18/05/21 Austrian Institute for Health Technology Assessment – AIHTA December 2020 No, stopped since May 2021  
RCR20 High-dose vitamin D 4.0 – 15/07/21 Gesundheit Österreich GmbH – GÖG February 2021 Yes, bi-monthly  
RCR21 Mavrilimumab 4.0 – 18/05/21 Servicio de Evaluación del Servicio Canario de la Salud – SESCS January 2021 Yes, monthly  
RCR22 Ivermectin 8.0 – 17/09/21 Agency for Health Technology Assessment and Tariff System – AOTMiT February 2021 Yes, monthly  
RCR23 Aspirin 8.0 – 22/09/21 Swiss Network for HTA – SNHTA February 2021 Yes, monthly  

*For monthly updated RCRs, the RCR authors search for new available evidence on a monthly basis. If new evidence is available, an updated report is published. In the case that no new evidence can be identified, no update is published, and the search is repeated in the subsequent month.

For bi-monthly updated RCRs, the RCR authors search for new available evidence every other month. If new evidence is available, an updated report is published. In the case that no new evidence can be identified, no update is published and the search is repeated after 2 months.

Please access a description of methods used in the RCR process here.

Stopping & Starting Rules for RCR

Stopping Rules

  • The decision to stop an RCR will be taken collectively in the RCR team.
  • A discussion about stopping an RCR will be started when either stopping rule 1 OR stopping rule 2 is met.
  • The stopping rules act as orientation/ reference for the discussion in the team; an RCR may not be stopped although one of the rules apply if the team comes to a different conclusion due to any sound reason.

Stopping rule 1:

The compound is in EMA’s marketing authorization process or has a positive marketing authorization decision.

Stopping rule 2:

No clinical benefit: ≥ 2 RCTs OR treatment arms in platform trials (e.g., RECOVERY) with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered).

OR ≥1 RCT with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered) AND stopped enrollment of participants to the treatment arm of interest in a platform trial (e.g., RECOVERY) because no evidence of beneficial effects.

  • To be considered for the discussion:
    • Amount and number of included patients of ongoing RCTs and upcoming RCTs

Starting rules

  • The decision to start an RCR will be taken collectively in the RCR team.
  • A discussion about starting an RCR will be started when one of the starting rules is met.
  • The starting rules act as orientation/ reference for the discussion in the team; an RCR may not be started although one of the rules apply if the team comes to a different conclusion due to any sound reason.

Starting rule 1:

Published results from ≥ 1 phase III RCT with positive efficacy and safety results in the indication and population under review (high or moderate quality, non peer-reviewed or peer-reviewed article).

  • Confirmed by DEPLazio or RCT found on covid-nma.com

Starting rule 2:

Upcoming (promising) evidence of ≥ 2 phase III trials.

Starting rule 3:

Compound included as trial drug in a platform trial on COVID-19 treatments.

Starting rule 4:

Combination therapy of ≥ 2 promising pharmaceuticals – the combination will be reviewed as a separate intervention.

Starting rule 5:

Interest from ≥ 2 EUnetHTA Partners (via survey) OR Interest from MAH to seek marketing approval OR Interest from EC, HTA Network or EUnetHTA Stakeholder Groups.

Rapid Collaborative Reviews

Please access the Rapid Collaborative Reviews in the following table.

Project ID Title Publication of Final Review Author Co-Author Dedicated Reviewer Publication of Project Plan
PTRCR20 Bamlanivimab for the treatment of COVID-19
Rapid Collaborative Review
31.05.2021 AIHTA  SNHTA SESCS, SUKL NA
PTRCR19  REGN-Cov2 for the treatment of COVID-19
Rapid Collaborative Review
21.05.2021 AIHTA  SNHTA GÖG, UCSC Gemelli NA
PTRCR18 Dexamethasone for the treatment of COVID-19
Rapid Collaborative Review
19.11.2020 AIHTA SNHTA RER, MoH Ukraine NA
PTRCR15

Remdesivir for the treatment of COVID-19

First update

First update: 16.12.2020 AIHTA NA INFARMED, NCPE, RER, MoH Ukraine NA
Rapid Collaborative Review: PICO and Evidence gaps Original report: 29.09.2020 INFARMED NCPE AIHTA, RER, MoH Ukraine NA

National HTA Organisation Treatment Links

Links will be published here that relate to relevant partner organisation outputs on Covid-19.

Austrian Institute for Health Technology Assessment (AIHTA) – Horizon scanning for Covid-19 treatments:

http://eprints.aihta.at/1234/

CountryOrganisationDate of publicationHTA reviews/assessments on Covid testing
IrelandAIFA26/04/21Raccomandazioni AIFA sui farmaci per la gestione domiciliare di COVID-19 (AIFA recommendations on drugs for the home management of COVID-19)
IrelandNCPE25/02/21Rapid Evidence Review – Tocilizumab in the management of COVID-19
IrelandNCPE25/02/21Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation
UKNICE24/02/21COVID-19 rapid evidence summary: Tocilizumab for COVID-19
IrelandNCPE19/02/21Intravenous immunoglobulin for the treatment of COVID-19: A Rapid Evidence Review
IrelandNCPE05/02/21Rapid Evidence Review – Clinical evidence for the use of antivirals in the treatment of COVID-19
SpainAEMPS25/01/211º Informe de Farmacovigilancia sobre vacunas COVID-19 (Pharmacovigilance Report on Vaccines COVID-19)
UKNICE
National Institute for Health and Care Excellence

20/01/21COVID-19 rapid evidence summary: Sarilumab for COVID-19
UKNICE
National Institute for Health and Care Excellence

15/01/21COVID-19 rapid evidence summary: Sarilumab for COVID-19
ItalyAIFA
13/01/21Vaccini COVID-19 (Covid-19 vaccines)
PortugalINFARMED
National Authority of Medicines and Health Products

23/12/20Vacinas COVID-19 (Covid-19 vaccines)
SpainAEMPS
15/12/20Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
FranceHAS
01/12/20Aspects immunologiques et virologiques de l’infection par le SARS-CoV-2 (Immunological and virological aspects of SARS-CoV-2 infection)
ItalyAIFA25/11/20Idrossiclorochina nella terapia dei pazienti adulti con COVID-19 (Hydroxychloroquine in the treatment of adult patients with COVID-19)
ItalyAIFA
25/11/20Idrossiclorochina nella terapia dei pazienti adulti con COVID-19 (Hydroxychloroquine in the treatment of adult patients with COVID-19)
ItalyAIFA
24/11/20Eparine a basso peso molecolare nei pazienti adulti con COVID-19 (Low molecular weight heparins in adult patients with COVID-19)
ItalyAIFA
24/11/20Remdesivir nella terapia dei pazienti adulti con COVID-19 (Remdesivir in the therapy of adult patients with COVID-19)
FranceHAS
10/11/20Tests diagnostiques pour différencier la COVID-19 des infections respiratoires hivernales en période de co-circulation des virus (Diagnostic tests to differentiate COVID-19 from winter respiratory infections in periods of virus co-circulation)
IrelandNCPE
23/10/20Clinical evidence for the use of antivirals in the treatment of COVID-19
SpainAEMPS
23/10/20Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
SpainAEMPS
23/10/20Sospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19 (Suspected adverse reactions reported with treatments used in COVID-19)
IrelandNCPE22/10/20Rapid Evidence Review – Clinical evidence for the use of antivirals in the treatment of COVID-19
ItalyAIFA
06/10/20Corticosteroidi nella terapia dei pazienti adulti con COVID-19 (Corticosteroids in the therapy of adult patients with COVID-19)
SpainAEMPS
02/10/20Información sobre investigación clínica sobre la COVID-19 (Information on clinical research on COVID-19)
FranceHAS
25/09/20Veille des études cliniques publiées pour certains médicaments du Covid-19 (Monitoring of published clinical studies for certain Covid-19 drugs)
SpainAQuAS22/09/20Símptomes de llarga durada o persistents en pacients amb infecció lleu-moderada per SARS-CoV-2 (COVID-19): revisió ràpida de la literatura i discussió del’evidència disponible (Long-term or persistent symptoms in patients with moderate SARS-CoV-2 infection (COVID-19): rapid literature review and discussion of available evidence )
PolandAOTMiT28/08/20Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation
IrelandNCPE
21/08/20Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation
FinlandFIMEA
07/08/20Fimea julkaisi arviointikoosteen remdesiviiristä COVID-19-taudin hoidossa (Fimea has published a summary of the evaluation of remdesivirir in the treatment of COVID-19)
PolandAOTMIT
06/08/20Przegląd doniesień naukowych dla kortykosteroidów stosowanych w COVID-19 (Assessment of the scientific reports for corticosteroids used in COVID-19 (version 1.0))
PolandAOTMIT
05/08/20Przegląd doniesień naukowych dla lopinawiru/rytonawiru stosowanych w COVID-19 (Overview of the scientific reports for lopinavir / ritonavir used in COVID-19 (version 1.0))
UKNICE05/06/20COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
ItalyAIFA
17/07/20Darunavir/cobicistat nella terapia dei pazienti adulti con COVID-19 (Darunavir / cobicistat in the treatment of adult patients with COVID-19 )
ItalyAIFA
17/07/20Lopinavir/ritonavir nella terapia dei pazienti adulti con COVID-19 (Lopinavir / ritonavir in the treatment of adult patients with COVID-19 )
ItalyAIFA17/07/20Farmaci utilizzabili per il trattamento della malattia COVID-19 (Drugs usable for the treatment of the disease COVID-19)
WalesHTW??/07/20Cytokine adsorbers for the treatment of cytokine
storm in people with severe coronavirus infection
UKNICE National Institute for Health and Care Excellence29/06/20COVID-19 rapid evidence summary: vitamin D for COVID-19
UKNICE
National Institute for Health and Care Excellence

05/06/20COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
UkraineMoH Ukraine
22/05/20Застосування ліків при COVID-19 (The use of drugs in COVID-19)
UKHealth Technology WalesXX/04/20

Plasmapheresis of convalescent plasma to confer passive immunity

IrelandHIQA15/04/20

Evidence Summary for COVID-19 Clinical Samples

UKNICE
National Institute for Health and Care Excellence
24/03/20COVID-19 rapid evidence summary: acute use of nonsteroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19